In the claims:

1. (Currently Amended) A method of ~~treatment of an individual suffering from a disease resulting from an abnormal expression of genes caused by aberrant splicing in cells due to either exon inclusion, exon skipping, or both exon inclusion and exon skipping the method~~ing cystic fibrosis comprising:

administering to, or expressing in, ~~said cells of the individual or to~~cells, tissue or organs of ~~said~~ an individual in need thereof ~~comprising said cells,~~ an effective amount of an alternative splicing factor (ASF) capable of at least partially correcting aberrant splicing of a transcript of a CTFR gene, thereby treating cystic fibrosis in said individual ~~for treating exon inclusion, exon skipping, or both exon inclusion and exon skipping, whereby said abnormal expression shifts towards normal expression of the gene~~.

2. (Cancelled)

3. (Currently Amended) A method according to Claim ~~2~~1, wherein the aberrant splicing is caused by a mutation 3849+10kb C>T of ~~the~~ said CTFR gene.

4. (Currently Amended) A method according to Claim ~~2~~1, wherein the aberrant splicing is caused by a mutation in the 5T allele of ~~the~~ said CTFR gene.

5. (Currently Amended) A method according to Claim 1, wherein ~~the~~ said ASF is selected from the group consisting of:

(a) a member of the SR protein;

(b) heterogeneous nuclear ribonucleoprotein A1;

(c) viral factor E4-ORF3; and

(d) viral factor E4-ORF6; ~~and~~

~~(e) an agonist of any one of (a) to (e).~~

6. (Currently Amended) A method according to Claim 1, wherein ~~the~~ said ASF is administered ~~to the cells or to the tissue or organs comprising the cells~~ in a pharmaceutically acceptable vehicle.

7. (cancelled)

8. (Currently Amended) A method according to Claim 6, wherein ~~the~~ said ASF is attached to a targeting moiety capable of binding specifically to said cells.